Intarcia Therapeutics

Intarcia Therapeutics, Inc. was a Boston-headquartered clinical-stage biopharmaceutical and drug-delivery company, founded in 1997 and once valued at roughly $5.5B, that developed the Medici Drug Delivery System — a matchstick-sized subdermal osmotic mini-pump engineered to stabilize therapeutic proteins and peptides at body temperature and release them continuously for months from a single placement. Its lead candidate, ITCA 650, delivered the GLP-1 receptor agonist exenatide for type 2 diabetes over three- to six-month intervals. The FDA issued complete response letters on the ITCA 650 new drug application in 2017 and again in 2020, after which the company ran out of capital, laid off staff, closed its Boston, Hayward (CA) and Durham (NC) sites and liquidated its manufacturing and laboratory equipment at auction. Its remaining assets — the Medici platform and ITCA 650 — were acquired by i2o Therapeutics in August 2023, and FDA published a final decision refusing to approve the ITCA 650 application on 2024-08-23. Intarcia was a drug-device developer rather than a software company: its corporate site carried only Medici System, Pipeline, Newsroom, About, Leadership and Careers sections and never published a developer program, public API, SDK, webhook surface or machine-readable specification of any kind. As of 2026-08-23 both intarcia.com and intarciatherapeutics.com resolve to an Atom.com domain-broker parking page that offers the names for sale and returns HTTP 404 on every path, and no developer-facing subdomain resolves. This profile is retained as a historical record; there is no API surface to enrich.

Intarcia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Defunct, Biotechnology, Pharmaceuticals, and Drug Delivery.

1.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0
0 APIs
CompanyDefunctBiotechnologyPharmaceuticalsDrug DeliveryMedical DevicesDiabetesHealthLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0
Composite quality — 1.8/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 3.9 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Delegated User Identity 0 / 6
Protected Resource Metadata 0 / 5
Registration Without a Human 0 / 6
Agentic Commerce Surface 0 / 5
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/intarcia-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑
aid: intarcia-therapeutics
name: Intarcia Therapeutics
description: 'Intarcia Therapeutics, Inc. was a Boston-headquartered clinical-stage biopharmaceutical and drug-delivery company,
  founded in 1997 and once valued at roughly $5.5B, that developed the Medici Drug Delivery System — a matchstick-sized subdermal
  osmotic mini-pump engineered to stabilize therapeutic proteins and peptides at body temperature and release them continuously
  for months from a single placement. Its lead candidate, ITCA 650, delivered the GLP-1 receptor agonist exenatide for type
  2 diabetes over three- to six-month intervals. The FDA issued complete response letters on the ITCA 650 new drug application
  in 2017 and again in 2020, after which the company ran out of capital, laid off staff, closed its Boston, Hayward (CA) and
  Durham (NC) sites and liquidated its manufacturing and laboratory equipment at auction. Its remaining assets — the Medici
  platform and ITCA 650 — were acquired by i2o Therapeutics in August 2023, and FDA published a final decision refusing to
  approve the ITCA 650 application on 2024-08-23. Intarcia was a drug-device developer rather than a software company: its
  corporate site carried only Medici System, Pipeline, Newsroom, About, Leadership and Careers sections and never published
  a developer program, public API, SDK, webhook surface or machine-readable specification of any kind. As of 2026-08-23 both
  intarcia.com and intarciatherapeutics.com resolve to an Atom.com domain-broker parking page that offers the names for sale
  and returns HTTP 404 on every path, and no developer-facing subdomain resolves. This profile is retained as a historical
  record; there is no API surface to enrich.'
url: https://raw.githubusercontent.com/api-evangelist/intarcia-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-secondary-market-listing: https://forgeglobal.com/intarcia-therapeutics_stock/
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: defunct
x-shutdown-note: Wound down after the FDA's second complete response letter in 2020; equipment liquidated at auction and the
  Medici / ITCA 650 assets acquired by i2o Therapeutics in August 2023. FDA published its final decision refusing approval
  of ITCA 650 on 2024-08-23.
x-successor: i2o Therapeutics (acquired the Medici Drug Delivery System and ITCA 650, 2023-08)
x-domain-status: parked-for-sale
x-domain-note: intarcia.com and intarciatherapeutics.com both resolve to 52.20.84.62 on ns1/ns2.atom.com and serve an Atom.com
  domain-broker landing page. Every /.well-known/ and spec path returns a hard HTTP 404 (679 bytes, identical to a nonsense
  control path), so there are no soft-200 false positives to guard against. These hosts are NOT company-controlled and are
  deliberately not wired as a Website pointer. See well-known/intarcia-therapeutics-well-known.yml.
x-venue-listing-note: The Forge Global secondary-market page this company was harvested from is recorded above as x-secondary-market-listing
  and is deliberately NOT wired as a common[] Website pointer — a trading-venue listing is not a company web presence (network
  roadmap#56).
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Defunct
- Biotechnology
- Pharmaceuticals
- Drug Delivery
- Medical Devices
- Diabetes
- Health
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common: []
x-coverage:
  state: none
  reason: defunct
  detail: Intarcia Therapeutics wound down after the FDA's 2020 complete response letter and sold the Medici / ITCA 650 assets
    to i2o Therapeutics in 2023; intarcia.com and intarciatherapeutics.com are now an Atom.com domain-broker parking page
    that hard-404s every /.well-known/ and spec path, and api., developer., docs., portal., dev. and app. subdomains do not
    resolve at all.
  evidence:
  - url: https://intarcia.com/
    status: 403
  - url: https://intarcia.com/zzz-control-nonsense-xyz789
    status: 404
  - url: https://intarcia.com/openapi.json
    status: 404
  - url: https://intarcia.com/llms.txt
    status: 404
  - url: https://intarcia.com/.well-known/agent-card.json
    status: 404
  - url: https://intarciatherapeutics.com/.well-known/agent.json
    status: 404
  - url: https://api.github.com/orgs/intarcia
    status: 200
  - url: https://forgeglobal.com/intarcia-therapeutics_stock/
    status: 403
  checked: '2026-08-23'
x-enrichment:
  date: '2026-08-23'
  status: nochange
  artifacts_added: 1
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/intarcia-therapeutics"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/intarcia-therapeutics/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/intarcia-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

A second provider on the same verified email joins the account you already have.